| Treatment or prevention of gastrointestinal immunotherapy side effects |
2023-8-08 |
2024-2-15 |
|
| Methods and compositions for attenuating antibiotic resistance |
2023-5-25 |
2023-12-14 |
|
| Ulcerative colitis treatments in selected patients |
2023-5-23 |
2023-11-30 |
|
| Modified beta-lactamases and methods and uses related thereto |
2023-5-10 |
2023-10-19 |
|
| Alkaline phosphatase agents for treatment of radiation disorders |
2023-4-14 |
2023-10-05 |
|
| Intestinal alkaline phosphatase formulations |
2023-3-17 |
2023-9-07 |
|
| Beta-lactamases with improved properties for therapy |
2023-2-07 |
2023-10-05 |
|
| Method and compositions for inhibiting or preventing adverse effects of oral … |
2023-2-02 |
2023-12-21 |
|
| E. coli-based production of beta-lactamase |
2022-12-01 |
2023-9-07 |
|
| Microbiome protection from oral antibiotics |
2022-10-26 |
2024-1-30 |
2024-1-30 |
| Alkaline phosphatase-based treatments of celiac disease |
2022-5-24 |
2022-12-01 |
|
| Alkaline phosphatase agents for treatment of neurodevelopmental disorders |
2022-4-21 |
2022-8-04 |
|
| Safe and effective beta-lactamase dosing for microbiome protection |
2022-1-10 |
2022-4-28 |
|
| Carbapenemases for use with antibiotics for the protection of the intestinal … |
2021-8-19 |
2022-1-06 |
|
| Alkaline phosphatase formulations |
2021-3-29 |
2021-7-22 |
|
| Beta-lactamase formulations and uses thereof |
2020-9-28 |
2021-1-14 |
|
| Intestinal alkaline phosphatase-based treatments of metabolic disorders |
2020-7-16 |
2023-2-22 |
|
| Alkaline phosphatase formulations and uses thereof |
2020-6-03 |
2020-12-10 |
|
| Beta-lactamase compositions for treatment of graft versus host disease |
2020-5-05 |
2021-10-28 |
|
| Alkaline phosphate-based oncology treatments |
2020-5-05 |
2020-11-12 |
|
| Methods of making alkaline phosphatase agents |
2019-6-17 |
2021-6-24 |
|
| Humanized pertussis antibodies and uses thereof |
2018-6-25 |
2018-12-20 |
|
| Beta-lactamase formulations |
2018-3-20 |
2020-4-09 |
|
| Stabilized pertussis antibodies with extended half-life |
2017-8-15 |
2021-10-28 |
|
| Use of viral vectors in the treatment of retinoblastoma |
2017-5-18 |
2019-11-21 |
|
| Anti-methanogenic compositions |
2017-5-12 |
2019-9-12 |
|
| Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and … |
2016-5-04 |
2018-3-14 |
|
| Anti-methanogenic lovastatin analogs or derivatives and uses thereof |
2016-3-31 |
2018-12-05 |
|
| Anti-methanogenic compositions and uses thereof |
2015-8-13 |
2017-2-02 |
|
| Modified beta-lactamases and methods and uses related thereto |
2014-2-28 |
2014-3-20 |
|
| Gastroretentive oral high dose zinc preparations |
2010-11-01 |
2012-6-14 |
|
| Medication dispensing package and method |
2008-7-10 |
2010-4-07 |
|
| Oral zinc medicants useful for safely lowering free copper absorption and free … |
2008-3-12 |
2013-1-16 |
|
| Modified beta-lactamase and method for its preparation |
2007-6-19 |
2011-8-02 |
2011-8-02 |
| Non-sporulating Bacillus subtilis having parts of the gene encoding sigma G … |
2002-11-05 |
2008-1-15 |
2008-1-15 |
| Traitement ou prévention d'effets secondaires d'immunothérapie gastro- … |
2023-8-08 |
2024-2-15 |
|